

EXHIBIT B.4

Plaintiffs' Trial Exhibit No	Description	Objections
0001	Internal Audit, 2007 Internal Audit Plan	*
0002	Disclosure Committee Charter	**
0003	Slappendale Sales Guide	*
0004	RC Reform, Why, What, When, How & Who	*
0005	Mary K. Jones purchase confirmation	**
0006	Mary K. Jones sell confirmation	**
0007	Philips purchase and sale summary of Pfizer stock from 12/06 through 01/09	**
0008	Handwritten Notes	
0009	Handwritten Notes	
0010	Handwritten Notes	
0011	Handwritten Notes	
0012	Handwritten Notes	
0013	Handwritten Notes	
0014	Handwritten Notes	
0015	Amendment of Articles of Philips Pensionfonds	**
0016	Amended and Restated Investment Management Agreement between Philips Investment Management and Stichting Philips Pensioenfonds	**
0017	Amended Certification of Named Plaintiff Pursuant to Federal Securities Laws	*
0018	Philips Purchase Confirmation	**
0019	Philips Purchase Confirmation	**
0020	Corporate Integrity Agreement	*
0021	Wunderink Reprint	*
0022	United States v. Pharmacia & Upjohn Co., Inc., No. 1:09-cr-10258-DPW, Settlement Agreement	*
0023	United States v. Pharmacia & Upjohn Co., Inc., No. 1:09-cr-10258-DPW, Sentencing Memorandum	*
0024	Pfizer Form DEF 14A Proxy	*
0025	Pfizer Form DEF 14A Proxy	*
0026	Greensmith Notebook #3	
0027	Greensmith Notebook #3	
0028	Greensmith Notebook #3	
0029	Greensmith Notebook #3	
0030	Greensmith Notebook #3	
0031	Creating Access to Innovation	*
0032	Neurontin CIA	*
0033	Celebrex and Bextra Monthly Dashboard for March 2004	*
0034	Bextra Anticipated Launch Publications	*
0035	POA 2004 Goals Cox-2	*
0036	Follow Up Notice Re Bextra Document Hold	**
0037	POA 1 2004 Pro Specialty	*
0038	Bextra Press Release	*
0039	DOJ Presentation	*
0040	DOJ Presentation	*
0041	DOJ Presentation	*
0042	DOJ Presentation	*
0043	DOJ Presentation	*
0044	DOJ Presentation	*
0045	DOJ Presentation	*
0046	DOJ Presentation	*
0047	DOJ Presentation	*
0048	Bristow Resume	*
0049	Letter from Pfizer	
0050	Letter and attached emails (compendium)	
0051	Memorandum	
0052	Mary K. Jones Revocable Trust	**
0053	Kopchinski Resume	
0054	Geodon FDA Approval Letter	*
0055	Geodon Verbatims	*

0056	Call Note for Geodon	*
0057	Email re Bextra	*
0058	Document re Vadecoxib	*
0059	Letter re NDA 21-341	*
0060	Email re JPT	*
0061	Second Amended Complaint	
0062	EMC Presentation	*
0063	Presentation re Bextra	*
0064	Email re Bextra	*
0065	Bextra Presentation -- So Much Power	*
0066	Geodon Verbatims	*
0067	Email re Bextra	*
0068	Email re Bextra	*
0069	Email re POA Presentation	*
0070	Email re Bextra	*
0071	Email re Bextra	*
0072	Email re Bextra	*
0073	Email re Bextra	*
0074	Email re Bextra	*
0075	Email re Promotion Guidelines	
0076	National Consultants' evaluation form	*
0077	Email re Bextra	*
0078	Email re Bextra	*
0079	Email re Bextra	*
0080	Presentation re Geodon	
0081	Email re NOW AVAIL PR	*
0082	Email re Bextra	*
0083	Questions re Bextra	*
0084	Email re Bextra	*
0085	Email re Geodn	*
0086	Email re Bextra	*
0087	Neil Kaye Key Selling Points	*
0088	FDA Letter re Geodon	*
0089	Email re Bextra	
0090	Email re Bextra	
0091	Geodon Call Notes	*
0092	Email re Dr. Kaye	*
0093	Email re Bextra	*
0094	Email re Speaker	*
0095	Email re Bextra	*
0096	FDA/DDMAC Untitled Letter re Geodon	*
0097	POA 3 Presentation	*
0098	Bextra Slides about two sales contests--Power Up and One-Two Punch	*
0099	Email re Bextra	
0100	Email re Key Message Meeting	*
0101	Call note	*
0102	Call note	*
0103	Email re Bextra	*
0104	Email re Strategic Platform	*
0105	Email re Bextra	
0106	2003 Celebrex and Bextra Operating Plan	*
0107	Email re Bextra	*
0108	Email re Dr. Kaye	*
0109	Email re Bextra	*
0110	2002 Corporate Integrity Agreement	*
0111	Presentation re Bextra	*
0112	Email re Arrowwood Feedback	*
0113	Email re Bextra	
0114	Email re Bextra	*
0115	Email re JVA	*
0116	Email re Bextra	*

0117	Email re Bextra	*
0118	Call Note for Geodon	*
0119	Geodon Verbatims	*
0120	Presentation	
0121	Email re Cox 2 Standing Orders	*
0122	Email re Geodon	*
0123	Email re Bextra	*
0124	Email re Bextra	*
0125	Email re Bextra	
0126	Bextra Call Note Summaries	*
0127	Email re Geodon	
0128	Email re Bextra	*
0129	Cox-2 Product Action Guide -- 2004	*
0130	Email re Bextra	*
0131	Survey of Doctors re Bextra Messaging	*
0132	Email re Cox-2 Tactical Plan	*
0133	Email re Standing Order Contest	*
0134	Email re Bextra	*
0135	Email re Feedback from Sales Force	*
0136	Email re Bextra	*
0137	Email re Bextra	*
0138	Email re Bextra	*
0139	Email re Bextra	*
0140	Email with Physician bio information	*
0141	Email re Bextra	*
0142	POA 2 Goals cox 2	*
0143	Email re Bextra	*
0144	Email re Bextra	*
0145	Email re Fast Facts	*
0146	Email re Bextra	*
0147	Email re Bextra	*
0148	Call note	*
0149	Email re Bextra	*
0150	Call note	*
0151	DM Working Sessions: Report	*
0152	Call note	*
0153	Email re Bextra	*
0154	Pfizer Blue Book	**
0155	Email re Bextra	*
0156	Call note	*
0157	Geodon Call Note	*
0158	Email re Bextra	*
0159	Call Note for Geodon	*
0160	Geodon 2004 Operating Plan	*
0161	Email re Bextra	*
0162	Email re Geodon	*
0163	Email re Geodon	
0164	Pro West POA 1 2004 Playbook	*
0165	Wunderink Reprint	*
0166	Call note	*
0167	Email re Influence Mapping	*
0168	Call note	*
0169	Geodon Verbatims	*
0170	Kollef Reprint	*
0171	Call note	*
0172	Email re Bextra	*
0173	2004 Product Action Guide- Northeast Guide Cox 2	*
0174	Call note	*
0175	Internal Audit Report: re US PGP Sales Operations Speakers Programs	*
0176	Email re Bextra	*
0177	Minutes: BOD Meeting	**

0178	Call note	*
0179	Email re Bextra	*
0180	Email re Geodon	*
0181	Call note	*
0182	Call note	*
0183	Email re Bextra	*
0184	Email re Bextra	*
0185	Email re Geodon	*
0186	Email re Bextra	*
0187	2004 Neurontin CIA	*
0188	Call Note for Geodon	*
0189	Plea Letter in United States v. Warner-Lambert Company LLC, No. 04-10150	*
0190	Information in United States v. Warner-Lambert Company LLC, No. 04-10150	*
0191	Government Sentencing Memorandum in United States v. Warner-Lambert Company LLC, No. 04-10150	**
0192	Call note	*
0193	Email re Impart Report	*
0194	Call note	*
0195	Presentation re Voluntary Disclosure	**
0196	Call Note for Geodon	*
0197	Email re Bextra	*
0198	Call note	*
0199	Memo re DOJ Investigation	**
0200	Call note	*
0201	Call note	*
0202	Call note	*
0203	Letter from NYAG Office	*
0204	Email re Geodon POA	
0205	FDA Letter to Brian Green re deferral of Geodon pediatric studies	*
0206	Email re Bextra	*
0207	Letter re Lyrica	*
0208	2005 Lyrica Operating Plan	*
0209	Email re COX2 Optimization	*
0210	Call Note for Geodon	*
0211	Email re Bextra	*
0212	Call note	*
0213	Call note	*
0214	Email re Bextra	*
0215	Letter re Corporate Integrity Agreement	*
0216	Product Action Guide	*
0217	Email re Lyrica	*
0218	Letter re Pfizer Bextra Call Notes	*
0219	2004 Feedback Form re Bextra	*
0220	SEC speech in which Deputy Chief Accountant opines that most companies' FAS 5 disclosures are not sufficient because disclosure/accrual happens too late	*
0221	Email re Bextra	*
0222	Medicine Net, "Bextra Label Updated with Boxed Warning Concerning Severe Skin Reactions and Warning Regarding Cardiovascular Risk," December 9, 2004 (available at http://www.medicinenet.com/script/main/art.asp?articlekey=40990)	*
0223	Email re Bextra	*
0224	Lyrica FDA Letter	*
0225	Presentation re Compliance	*
0226	Geodon Verbatims	*
0227	Weigelt Reprint	*
0228	Memorandum re: Interview of Alex Alvarez on December 16, 2004	*
0229	Memorandum re: Interview of Tom Farina on December 16, 2004	*
0230	Letter re Bextra	*

0231	Call note	*
0232	Call note	*
0233	Covington memo of interview with Bermudez	*
0234	Call note	*
0235	Email re Geodon	*
0236	Memo of interview with Gorelik	*
0237	Covington Memo of Interview with Farina	*
0238	Email re Management Structure	*
0239	2004 Form 10-K and attached SOX certifications	**
0240	Target Rx Detail Performance	*
0241	Fax from DDMAC	*
0242	Neuropathic Pain Implementation Guide	*
0243	Lyrice Visual Aid	*
0244	Call Note for Geodon	*
0245	Call Note for Geodon	*
0246	Internal Audit Report: T&E	*
0247	Press Release re Bextra	*
0248	Compliance Quarterly Matters Report	*
0249	Press Release re Cox-2	*
0250	Letter re Document Issues in the Bextra Investigation	*
0251	Call note	*
0252	Call note	*
0253	Call note	*
0254	Call note	*
0255	Audit Committee Materials	*
0256	Email re Lyrice	*
0257	Email re Lyrice	*
0258	Audit Committee Minutes	*
0259	Email re FAQs - Compliance Related Questions	*
0260	Wunderink Reprint	*
0261	Call Note for Geodon	*
0262	Lyrice FDA Approval Letter	*
0263	Call note	*
0264	Call note	*
0265	FDA Warning Letter re Zyvox	*
0266	Email re Lyrice	*
0267	Email re Lyrice	*
0268	Email re Zyvox	*
0269	Pfizer Inc. Corporate Integrity Agreement Annual Report	*
0270	Email re September 2005 POA	*
0271	Email re Zyvox	**
0272	Gedon Call Note	*
0273	Letter re Bextra	**
0274	Call note	*
0275	Call note	*
0276	Email re Zyvox	*
0277	Email re Lyrice	*
0278	Email re POA1 for 2006	*
0279	Call note	*
0280	2006 Zyvox Operating Plan	*
0281	Letter from DOJ setting the agreement between U.S. and Serono Laboratories, Inc.	*
0282	Memo re Reserve Review Meeting	*
0283	HawkPartners Memo	*
0284	Call note	*
0285	Email re Lyrice	*
0286	Letter re Bextra Investigation	*
0287	Call note	*
0288	Geodon Call Note	*
0289	2006 Strategic & Operating Plan	*
0290	Audit Committee Compliance Update	**
0291	Internal Audit Report: Call Notes and Email	*

0292	Email re Internal Audit Report	*
0293	Geodon Verbatims	*
0294	Dep't of Health and Human Services OIG Report of Interview with Alvarez (1/6/2006)	*
0295	4Q05/FY05 Form 8-K Earnings Press Release	**
0296	"Drug Makers Deliver Weak Earnings --- Generics Weigh on Pfizer; Novartis Net Comes In Flat Despite 14% Rise in Sales," by Scott Hensley and Anita Greil, The Wall Street Journal, 20 January 2006	*
0297	Workpaper re Sales Force Training	*
0298	Email re Zyvox	*
0299	Lyrice Early User Research Wave II- Qualitative Research with Physicians FINAL REPORT	*
0300	Analyst Meeting transcript	*
0301	Influencing the Environment, 2006 CIA Risk Inventory & Analysis	*
0302	2005 Form 10-K	**
0303	2006 Form DEF 14A Proxy	**
0304	Sharpe reprint	*
0305	Lyrice Profiler	*
0306	Geodon issues	*
0307	Zyvox Target Rx Detail Performance	*
0308	FDA/DDMAC Warning Letter re Zyrtec	*
0309	1Q06 Form 8-K Earnings Press Release	**
0310	Unrated Internal Audit Memo	*
0311	1Q06 Form 10-Q	**
0312	Email re Lyrice	*
0313	Email re Total Honoraria for 2005 Speakers Events	*
0314	Philips Purchase Confirmation	**
0315	Philips Purchase Confirmation	**
0316	Philips Purchase Confirmation	**
0317	Philips Purchase Confirmation	**
0318	FDA Office of Criminal Investigations Memorandum of Interview Alex Alvarez	*
0319	Internal Audit Report: Marketing Promotional Speakers Programs	*
0320	Email re Kaye Slides	*
0321	Wave 3 qualitative research by HawkPartners	*
0322	Notes from Lyrice POA II meeting	*
0323	"PFE: Sale of Consumer Health Accretive Beyond 2007, Reiterate \$29.50 Fair Value Estimate," by Jon LeCroy, M.D., and Stephen B. Shankman, Natexis Bleichroder, Inc., analyst report, 23 June 2006	*
0324	"Expanding Buybacks with Sale Proceeds Increases Shareholder Value," by Jami Rubin, et al., Morgan Stanley, analyst report, 26 June 2006	*
0325	"PCH Divestiture Magnifies Lipitor/tocetrapib's Importance on Revenues and Cash Flow," by Catherine J. Arnold, Credit Suisse, analyst report, 26 June 2006	*
0326	Philips Purchase Confirmation	**
0327	Philips Purchase Confirmation	**
0328	2Q06 Form 8-K Earnings Press Release	**
0329	McKinnell Form 4	*
0330	Lyrice US Operating Plan	*
0331	Memo re Compliance Issues Summary	**
0332	2007 Zyvox Operating Plan	*
0333	2Q06 Form 10-Q	**
0334	Email re Lyrice	*
0335	Letter re Pfizer's Organizational Structure	*
0336	Presentation re Bextra	*
0337	Presentation re Bextra	*
0338	Presentation re Bextra	*
0339	Levin Form 4	*
0340	Email re August 2006 Financial Controls Report	**
0341	Philips Purchase Confirmation	**

0342	Pfizer Inc. Corporate Integrity Agreement Annual Report	**
0343	Email September 2006 Monthly Financial Controls Report	**
0344	Presentation re Bextra	*
0345	DOJ Presentation	*
0346	DOJ Presentation	*
0347	Letter to OIG	*
0348	ELT Meeting Minutes	*
0349	Audit Committee of the BOD: Legal Review	**
0350	Geodon issues	*
0351	Unrated Internal Audit Memo	*
0352	Minutes: Disclosure Committee Meeting	**
0353	Internal Audit Unrated Memo re Promotional Expenses and Promotional Funds/Remediation Status	*
0354	Email re Q3 Earnings: Top analyst and media questions	*
0355	Email re Lyrica	*
0356	Email re Lyrica	*
0357	3Q06 Form 8-K Earnings Press Release	**
0358	Dep't of Health and Human Services OIG Report of Interview with Bermudez (10/23/2006)	*
0359	Email re US Compliance Issues	*
0360	Memo re Procedures for SEC Certification	*
0361	Final Minutes: Disclosure Committee Meeting	*
0362	3Q06 Form 10-Q	**
0363	Email re US HCC Remediation Plan	*
0364	Email re HCC Controls	*
0365	Letter re Pfizer sales force	*
0366	Email re Zyvox	*
0367	Pfizer Inc., Audit Committee of the Board of Directors, Compliance Update	*
0368	Philips Purchase Confirmation	**
0369	Geodon Verbatims	*
0370	United States v. Schering Sales Corp., No. 06-10260-PBS, Government's Sentencing Memorandum	*
0371	Analyst Meeting transcript	*
0372	4Q06/FY06 Form 8-K Earnings Press Release	**
0373	Internal Control Deficiencies -- KPMG Approach	*
0374	Supplemental Response to ROGS	*
0375	Email re Select Product Performance	*
0376	Read Form 4	*
0377	Memo re Internal Controls	*
0378	Internal Audit Report: Publications and Authorships	*
0379	Email re Internal Audit Reports	*
0380	Email re Lyrica	*
0381	Memo re Sales and Compliance Discussion	*
0382	2006 Form 10-K	**
0383	Zyvox Target Rx Detail Performance	*
0384	Memo re Bextra Document Hold	**
0385	Email re Zyvox	*
0386	2007 Form DEF 14A Proxy	*
0387	Letter from Ian Read and George Henninger to Pfizer Audit Committee	*
0388	Philips Purchase Confirmation	**
0389	Letter re Pharmacia & Upjohn Company LLC	*
0390	Letter re Plea in United States v. Pharmacia & Upjohn Company, Inc.	*
0391	Press release regarding settlement of Genotropin investigation	*
0392	The Indianapolis Star: Denials over drug's diabetes link, negative publicity led to loss of \$65 billion in value	*
0393	Email re Geodon	*
0394	Philips Purchase Confirmation	**
0395	1Q07 Form 8-K Earnings Press Release	**
0396	Memo re Internal Controls	*
0397	1Q07 Form 10-Q	**

0398	Philips Purchase Confirmation	**
0399	Levin Form 4	*
0400	Email re Geodon	*
0401	Email re Geodon	*
0402	Email re Geodon	*
0403	Zyvox POA 2	*
0404	Philips Purchase Confirmation	**
0405	Philips Purchase Confirmation	**
0406	Philips Purchase Confirmation	**
0407	Philips Purchase Confirmation	**
0408	Philips Purchase Confirmation	**
0409	Lyrice Verbatims	*
0410	Internal Audit, Audit Report, Worldwide Pharmaceutical Operations, US Field Force Travel & Entertainment Expenses, New York Headquarters	*
0411	Email re Audit Committee Pre-Read	*
0412	Email re Zyvox	*
0413	Letter to Posner	*
0414	Memo to the Audit Committee	*
0415	Philips Purchase Confirmation	**
0416	Email re Potential Audit Committee Questions	*
0417	Email re Geodon	*
0418	Audit Committee Minutes	**
0419	Memo: 2007 Mid-Year Progress Report	*
0420	Philips Purchase Confirmation	**
0421	Mid POA 2007 Lyrice/Geodon	*
0422	Letter re Lyrice Subpoena	*
0423	FDA/DDMAC Untitled Letter re Geodon	*
0424	Philips Purchase Confirmation	**
0425	2Q07 Form 8-K Earnings Press Release	**
0426	Philips Purchase Confirmation	**
0427	Philips Purchase Confirmation	**
0428	Philips Purchase Confirmation	**
0429	USPO Compliance document	*
0430	Memo re HCC Controls	*
0431	Philips Purchase Confirmation	**
0432	Email re Select Product Updates	*
0433	Letter to OIG	*
0434	Philips Purchase Confirmation	**
0435	2Q07 Form 10-Q	**
0436	Philips Purchase Confirmation	**
0437	Philips Purchase Confirmation	**
0438	Email re Zyvox	*
0439	Philips Purchase Confirmation	**
0440	Philips Purchase Confirmation	**
0441	Philips Purchase Confirmation	**
0442	Pfizer Inc. Corporate Integrity Agreement Annual Report	**
0443	Philips Purchase Confirmation	**
0444	Email re Resignation	*
0445	Email re Zyvox	*
0446	Philips Purchase Confirmation	**
0447	Philips Purchase Confirmation	**
0448	Philips Purchase Confirmation	**
0449	Lyrice Verbatims	*
0450	2008 Zyvox Operating Plan	*
0451	Email re Bextra DOJ	**
0452	Email re Disclosure	**
0453	Email re Dividend	*
0454	3Q07 Pfizer earnings conference call transcript	*
0455	3Q07 Form 8-K Earnings Press Release	**
0456	Email re Zyvox	*
0457	Philips Purchase Confirmation	**

0458	Handwritten Notes	*
0459	Email re Dividend	*
0460	Email re Zyvox	*
0461	Email re Reserving and Settlement Procedures	*
0462	Email re Zyvox	*
0463	Philips Purchase Confirmation	**
0464	Philips Purchase Confirmation	**
0465	3Q07 Form 10-Q	**
0466	Read Form 4	*
0467	Email re Dividend	*
0468	Philips Purchase Confirmation	**
0469	WPO Compliance, Compliance Strategy Update	*
0470	Letter re Pfizer Investigation	*
0471	Philips Purchase Confirmation	**
0472	Philips Purchase Confirmation	**
0473	Philips Purchase Confirmation	**
0474	Philips Purchase Confirmation	**
0475	Philips Purchase Confirmation	**
0476	POA 1 and 2 2006 Resource Guides	*
0477	Philips Purchase Confirmation	**
0478	Email re Zyvox	*
0479	"PFE: Potential Upside for Lipitor and Compelling Yield; Upgrading to Buy," by Jon LeCroy, Natixis Bleichroeder, analyst report, 23 January 2008	*
0480	"Raising EPS Forecasts; Shares Trading At Floor Valuation," by Chris Schott, et al., Bank of America, analyst report, 23 January 2008	*
0481	"Consistently Delivering on Near Term Targets," by Barbara Ryan and George Drivas, Deutsche Bank, analyst report, 23 January 2008, consolidation."	*
0482	"Solid Quarter; Raising Numbers; Fundamental Thesis Stays the Same," by Jami Rubin, et al., Morgan Stanley, analyst report, 23 January 2008	*
0483	"Defensive Short-term; Risky Longer-term," by Roopesh Patel, et al., UBS, analyst report, 23 January 2008	*
0484	"4Q07 Results - First Take," by Barbara Ryan and George Drivas, Deutsche Bank, analyst report, 23 January 2008	*
0485	"Positive 4Q Earnings Surprises But Very Different Outlooks," by Catherine J. Arnold and Michael Faerm, Credit Suisse, Pfizer & Abbott analyst report, 23 January 2008	*
0486	4Q07/FY07 Form 8-K Earnings Press Release	**
0487	"What Happened Last Quarter," by Devina Mehra and Kavita Thomas, First Global, 25 January 2008	*
0488	Philips Purchase Confirmation	**
0489	Philips Transaction Summary	**
0490	Tracking Chart	*
0491	Letter/fax from DOJ	**
0492	Trademark Assignment Abstract of Title	
0493	Pfizer article	*
0494	"Acquires Encysive For PAH," by Robert Hazlett and James Tumbrink, BMO, analyst report, 2/21/2008	*
0495	Email re Zyvox	*
0496	Philips Purchase Confirmation	**
0497	"March 5th Meeting Could Be a Mixed Bag," by Roopesh Patel, et al., UBS, analyst report, 29 February 2008	*
0498	2007 Form 10-K	**
0499	Email re Daily Street Report Headlines	*
0500	Philips Purchase Confirmation	**
0501	"Our Thoughts on PFE's Analyst Meeting," by John Boris, et al., Bear Stearns, analyst report, 6 March 2008	*
0502	"Between a Rock and Hard Cash Place," by Barbara Ryan, Deutsche Bank, analyst report, 5 March 2008	*
0503	Analyst Meeting transcript	**

0504	"Best Foot Forward, but Uncertain Footing Ahead," by David Risinger, et al., Merrill Lynch, analyst report, 6 March 2008	*
0505	"Is Pfizer Doing What Matters?" by Catherine J. Arnold, et al., Credit Suisse, Pfizer, Wyeth, Amgen, analyst report, 6 March 2008	*
0506	"PFE Analyst Day: No Big Deals, No Surprises," by Seamus Fernandez and Kathryn C. Alexander, Leerink Swann, analyst report, 6 March 2008	*
0507	Email re Analyst Report	*
0508	Philips Purchase Confirmation	**
0509	Email re POA 2 Zyvox	*
0510	2008 Form DEF 14A Proxy	*
0511	Philips Purchase Confirmation	**
0512	Email re Speakers Programs	*
0513	Letter re Bextra	*
0514	Email re Bextra DOJ	**
0515	Letter re Partially Unsealed Qui Tams Against Pfizer Inc.	*
0516	Philips Purchase Confirmation	**
0517	"1Q08 Earnings Preview: Volumes Declining," by John Boris, et al., Bear Stearns, analyst report, 15 April 2008,	*
0518	Philips Purchase Confirmation	**
0519	"1Q08 Results - First Take," by Barbara Ryan and George Drivas, Deutsche Bank, analyst report, 17 April 2008	*
0520	"Quick Comment: 1Q08 Disappoints; Lipitor Misses," by Jami Rubin, et al., Morgan Stanley, analyst report, 17 April 2008	*
0521	"Pfizer Profit, Sales Drop After US License Losses," Agence France Presse, 17 April 2008	*
0522	1Q08 Form 8-K Earnings Press Release	**
0523	"Corporate News: Pfizer Net Drops 18% As Rivals Strengthen," by Avery Johnson, The Wall Street Journal, 18 April 2008	*
0524	"Pfizer: Near-Term Miss; Long-Term Strategy Unclear," by Tim Anderson, et al., Bernstein, analyst report, 18 April 2008	*
0525	"1Q08 Disappointing But Outlook For Full Yr. Unchanged," by Barbara Ryan and George Drivas, Deutsche Bank, analyst report, 18 April 2008	*
0526	Philips Purchase Confirmation	**
0527	Email re COX-2 Litigation	*
0528	1Q08 Form 10-Q	**
0529	Email re Dividend	*
0530	Philips Purchase Confirmation	**
0531	Deutsche Bank Health Care Conference transcript	*
0532	Pfizer Inc. Ongoing Investigations and Legal Proceedings	**
0533	Email re Study 1002	*
0534	"High Yields, Easy Picks," by Steve E. Livingston, Washington Post, 1 June 2008	*
0535	Email re Dividend	*
0536	"Cash Flows Support Dividend," by Barbara Ryan, Deutsche Bank, analyst report, 3 June 2008	*
0537	"Dividend May Test Pfizer; Company's Funding Of Generous Payout Could Face Hurdles," by Avery Johnson and Joann S. Lublin, The Wall Street Journal, 3 June 2008	*
0538	WSJ article re: Dividend Could Test Pfizer	*
0539	Philips Purchase Confirmation	**
0540	Letter from Ian Read	*
0541	"Dueling Fools: Pfizer Bear," by Brian Lawler, Motley Fool, 11 June 2008	*
0542	Email re ELT Materials	*
0543	Philips Purchase Confirmation	**
0544	Email re Zyvox	*
0545	Philips Purchase Confirmation	**
0546	"Challenging Road Ahead - Initiating Coverage With Neutral Rating," by Chris Schott, et al., JPMorgan, analyst report, 24 June 2008	*
0547	Philips Purchase Confirmation	**
0548	Email re Disclosure	**

0549	"Growth Outlook Troubling, by John Boris, et al., Citigroup, analyst report, 17 July 2008	*
0550	"Ahead of the Bell: Pfizer rises on earnings," Associated Press, 23 July 2008	*
0551	"2Q08 Results - First Take," by Barbara Ryan and George Drivas, Deutsche Bank, analyst report, 23 July 2008	*
0552	"Second Quarter Revenue Above Expectations," by Stephen A. O'Neil, Hilliard Lyons, analyst report, 23 July 2008	*
0553	"FX, Cost Control Drive Modest EPS Beat," by Chris Schott, et al., JPMorgan, analyst report, 23 July 2008	*
0554	"Weak Dollar, Foreign Sales Boost Drugmakers," by Linda Johnson, Associated Press, 23 July 2008	*
0555	2Q08 Form 8-K Earnings Press Release	**
0556	Email re Disclosure	*
0557	2Q08 Form 10-Q	**
0558	"Sales & EPS Raised in 2011-12 But Still-Negative Outlook Keeps Us on Sidelines," by Seamus Fernandez and Kathryn Alexander, Leerink Swann, analyst report, 11 August 2008	*
0559	Verbatims Zyvox	*
0560	Email re Zyvox	*
0561	"What's New In The 10-Q?" by Steve Scala, et al., Cowen and Company, analyst report, 19 August 2008	**
0562	Email re Zyvox	*
0563	Email re Anti-Infective Communication	*
0564	Memo re Changes to Tracking Chart	*
0565	Compliance Matters Tracking Chart	*
0566	Memo to the Audit Committee	*
0567	"JAK3: Intriguing Phase IIb Data But Several Questions For ACR," by Chris Schott, et al., JPMorgan, analyst report, 15 September 2008	*
0568	UBS Conference transcript	*
0569	Email re Meeting with Analyst	*
0570	Philips Purchase Confirmation	**
0571	"Pfizer Plans to Abandon Heart-Drug Development," by Shirley Wang and Joann Lublin, The Wall Street Journal, 30 September 2008	*
0572	"Truth Be Told," by Catherine J. Arnold, et al., Credit Suisse, analyst report, 30 9/1/2008	*
0573	Email re Zyvox 2009 Budget	*
0574	Philips Purchase Confirmation	**
0575	"Pension Palpitations: Investors focusing on who may have problems," by Michael Moran and Abby Joseph Cohen, Goldman Sachs, Global Markets Institute, 13 October 2008	*
0576	"3Q08 Preview: Focus on US Operating Performance," by John Boris, et al., Citigroup, analyst report, 16 October 2008	*
0577	"Sales & EPS Reduced in '08-'12 Reflecting Fx & Q3 Rx Trends," by Seamus Fernandez and Kathryn Alexander, Leerink Swann, analyst report, 16 October 2008	*
0578	Articles re Pfizer To Take \$894 Million Charge For Legal Settlement, 17 October 2008	*
0579	"Drugmaker Pfizer Posts Big Jump In 3Q Profit Due To Charge A Year Ago, But Sales Are Flat," by Linda A. Johnson, Associated Press Newswires, 21 October 2008	*
0580	"Cost Savings On Track; Next Act, Products?" by Catherine J. Arnold, et al., Credit Suisse, analyst report, 21 October 2008	*
0581	"3Q Results: Good, Not Great; Waiting For LT Cost Clarity," by Chris Schott, et al., JPMorgan, analyst report, 21 October 2008	*
0582	"3Q08 Results - First Take," by Barbara Ryan and George Drivas, Deutsche Bank, analyst report, 21 October 2008	*
0583	"Still Paying Dividends, Reiterate Buy," by Barbara Ryan and George Drivas, Deutsche Bank, analyst report, 21 October 2008	*
0584	Market Share Analysis for Zyvox	*
0585	"Update 4-Pfizer Cost Cuts Help, But Street Pines For Deals," Reuters, 21 October 2008	*

0586	3Q08 Form 8-K Earnings Press Release	**
0587	"PFE -OK 3Q08 but Needs Some Direction," by C. Anthony Butler, Barclays, analyst report, 22 October 2008	*
0588	"Pfizer: 3Q In-Line; The Last of the Currency Tailwinds? Lowering EPS in 2008 Given USD Strengthening," by Tim Anderson, et al., Bernstein, analyst report, 22 October 2008	*
0589	Email re Meeting Materials	*
0590	Philips Purchase Confirmation	**
0591	Philips Purchase Confirmation	**
0592	Philips Purchase Confirmation	**
0593	Philips Purchase Confirmation	**
0594	Philips Purchase Confirmation	**
0595	Philips Purchase Confirmation	**
0596	Philips Purchase Confirmation	**
0597	Philips Purchase Confirmation	**
0598	"Lightens Up on Obesity Drug- Unsurprising," by Roopesh Patel and Keyur Parekh, UBS, analyst report, 6 November 2008	*
0599	"Initiation On Large-Cap Pharma: Dramatic Change Is Imperative," by Jami Rubin, et al., Goldman Sachs, pharmaceuticals analyst report, 6 November 2008	*
0600	"Incremental Steps Are Not Enough - Initiate With A Sell," by Jami Rubin, et al., Goldman Sachs, analyst report, 6 November 2008	*
0601	3Q08 Form 10-Q	**
0602	Email re Investor Sentiment	*
0603	"3Q08 10Q Assessed -Looking for New Adapting to Scale Initiative," by John Boris, et al., Citigroup, analyst report, 13 November 2008	*
0604	"Focused on Cash Deployment Opportunities. Initiate at Buy," by Steven M. Lichtman, et al., Bank of America, analyst report, 14 November 2008	*
0605	Email re Project Burgundy	*
0606	Philips Purchase Confirmation	**
0607	"Industry Consolidation We See M&A Accelerating: Line Up The Usual Suspects," by Barbara Ryan and George Drivas, Deutsche Bank, industry analyst report, 24 November 2008	*
0608	"Quick Comments From Our CFO Meeting," by David Risinger, et al., Merrill Lynch, analyst report, 3 December 2008	*
0609	"Dividend Announcement Likely Next Week: We Expect Sustainability," by Steven Lichtman, et al., Bank of America, analyst report, 10 December 2008	*
0610	"Initiating Coverage With a Buy: Risk/Reward Compelling as Bad News Priced In," by Manoj Garg, Soleil, analyst report, 10 December 2008	*
0611	Email re Dividend	*
0612	"Three Ways of Looking at Pfizer's Flat Dividend," by Jacob Goldstein, The Wall Street Journal Health Blog, 16 December 2008	*
0613	Philips Purchase Confirmation	**
0614	The White Guide	**
0615	Philips Purchase Confirmation	**
0616	"Our Thoughts on Price Increases, Rebates &M&A," by John Boris, et al., Citigroup, analyst report, 6 January 2009	*
0617	"Good for Defense, But Long-Term Outlook Requires Better Offense," by Seamus Fernandez and Kathryn C. Alexander, Leerink Swann, analyst report, 8 January 2009	*
0618	"Record S&P 500 Pension Deficit in 2008; Is There an Investment Solution?" by David Bianco, et al., Equity Strategy research report, 9 January 2009	*
0619	"Removing Pfizer from Americas Sell List," by Jami Rubin, et al., Goldman Sachs, analyst report, 11 January 2009	*
0620	Philips Purchase Confirmation	**
0621	Email re WJS Article	*
0622	Email re Analyst Report	*

0623	"4Q and FY08 Earnings Preview," by Anthony Butler, Barclays, analyst report, 23 1/1/2009	*
0624	"Quick Take: Combination Looks Solid For PFE Shareholders; Less So For WYE's," by Steve Scala, et al., Cowen and Company, analyst report, 23 January 2009	*
0625	"Potential Deal Makes Strategic Sense – Must Be a First Step," by Jami Rubin, et al., Goldman Sachs, analyst report, 23 January 2009	*
0626	"Pfizer in Talks to Buy Wyeth," by Matthew Karnitschnig and Jonathan D. Rockoff, The Wall Street Journal, 23 January 2009	*
0627	"Pfizer, Wyeth Deal Expected In 'Near Term' – CNBC's Faber," Dow Jones Newswires, 23 January 2009	*
0628	Minutes: Disclosure Committee Meeting	**
0629	"Shifting to More Conserv. Div Rating," by David Risinger, et al., Bank of America/Merrill Lynch, analyst report, 23 January 2009	*
0630	"WYE Deal Will Help; Doesn't Solve Problem," by Roopesh Patel and Keyur Parekh, UBS, analyst report, 23 January 2009	*
0631	"At \$60B, We Estimate PFE/WYE Deal Accretive With or Without Synergies," by Seamus Fernandez and Kathryn Alexander, Leerink Swann, analyst report, 23 January 2009	*
0632	"Pfizer, Wyeth: Tie-Up Could Be Highly Accretive; But From There, PFE Becomes A Bond," by Tim Anderson, et al., Bernstein, analyst report, 23 January 2009	*
0633	"Quick Take - Pfizer Buying Wyeth? Fits Our Thesis. Dividend at Risk?" BernsteinResearch	*
0634	WSJ article re: Pfizer's potential buyout of Wyeth	*
0635	"WSJ: Pfizer Seen Paying \$65B-\$70B To Buy Wyeth -- Sources," by Matthew Karnitschnig and Sarah Rubenstein, Dow Jones Newswires, 23 January 2009	*
0636	"PFE Reportedly to Buy WYE ~\$50/Share; Cut Dividend in Half," UBS Investment Research	**
0637	"PFE + WYE = Transformative Potential, But the Devil May Be in the Details," by Seamus Fernandez and Kathryn Alexander, Leerink Swann, analyst report, 26 January 2009	**
0638	"Pfizer/Wyeth Combination Improves Pfizer's Outlook," by Catherine Arnold, et al., Credit Suisse, Pharmaceuticals analyst report, 26 January 2009	**
0639	"Quick Take: Combination Looks Solid For PFE Shareholders; Less So For WYE's," by Steve Scala, et al., Cowen and Company, analyst report, 26 January 2009	**
0640	"Pfizer 'AAA' Rating On Watch Negative After Agreement To Buy Wyeth For \$68B," Standard & Poor's RatingsDirect, 26 January 2009	**
0641	"Quick Take - Pfizer Buying Wyeth - Should be Highly Accretive" Bernstein Research	**
0642	"Update: S&P, Moody's Weighing Downgrade of Pfizer," Dow Jones Newswires, 26 January 2009	*
0643	"Fitch Downgrades Pfizer, Inc.'s IDR to 'AA'; Rating Watch Negative," Business Wire, 26 January 2009	**
0644	"Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter," company press release, PR Newswire, 26 January 2009	*
0645	Market Watch: "Pfizer to Buy Wyeth in \$68 bln consolidation move..."; and "reported a 90% plunge in fourth-quarter profit, stemming mostly from a large legal settlement."	*
0646	Bloomberg article re: Pfizer Bextra settlement	*
0647	CNN article: Pfizer to buy Wyeth for \$68 billion	*
0648	National news briefs, Wenatchee World	*
0649	Record Searchlight: Pfizer to buy Wyeth for \$68 billion, cut jobs	*
0650	WSJ HEALTH BLOG: Pfizer Takes \$2.3B Charge Tied To Bextra Probe	*
0651	AP: Pfizer 4Q profit plunges on legal charges	*
0652	Dow Jones Newswires: Pfizer Confirms \$68B Deal To Buy Wyeth; 4Q Net Down 90%	*
0653	Financial Times: Pfizer pays \$68bn for Wyeth	*
0654	The Guardian: Pfizer to buy rival Wyeth for \$68bn	*

0655	Pfizer Press Release, "Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company"	**
0656	"Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter," company press release, PR Newswire, 26 January 2009	*
0657	Wyeth acquisition analyst call transcript	**
0658	4Q08/FY08 Form 8-K Earnings Press Release	**
0659	Email re Bextra	*
0660	"Perfect Storm of Uncertainty Taints Solid Strategic Acquisition," by Seamus Fernandez and Kathryn C. Alexander, Leerink Swann, analyst report, 27 January 2009	**
0661	"Combined PFE/WYE Offers Better Growth Than PFE Alone But With Added Risk," by Steve Scala, et al., Cowen and Company, analyst reports, 27 January 2009	**
0662	"PFE Agrees to Acquire Wyeth, Reports 4Q Results, Cuts Dividend," by Stephen O'Neil, Hilliard Lyons, analyst report, 27 January 2009	**
0663	"Pfizer Discount and Deal Risk Perceptions Create Opportunity – Reiterate Buy and \$50 Price Target," by David Moskowitz, RPh., and James Molloy, Caris & Company, analyst report, 27 January 2009	**
0664	WALL STREET JOURNAL ABSTRACTS: Pfizer sets \$2.3 billion settlement	*
0665	N.Y. Times: For Pfizer, A Big Deal And a Test	*
0666	Globe and Mail: Growth seen as obstacle for Pfizer-Wyeth behemoth	*
0667	WSJ: Pfizer is still vulnerable despite Wyeth purchase --- Growth prospects remain issue in wake of \$68 billion deal	*
0668	WSJ: Pfizer Sets \$2.3 Billion Settlement --- Agreement With U.S. Tied to Alleged Off-Label Marketing of Painkiller Bextra	*
0669	WSJ: Doubts Emerge Over Deal to Buy Wyeth	*
0670	"The Wyeth Purchase: Activity Yes, But Progress?" by Robert Hazlett and James Tumbrink, BMO, analyst report, 28 January 2009	**
0671	Drug Industry Daily: Pfizer to Pay Billions for Alleged Off-Label Promotions	*
0672	Email re Bextra Settlement	*
0673	"Attractive Risk-Reward - Upgrading to Buy," UBS Investment Research	**
0674	Pfizer Form DEF 14A Proxy	*
0675	Email re Zyvox	*
0676	Mary Holloway's Sentencing Memorandum	
0677	Plea Agreement in United States v. Pharmacia & Upjohn Company, Inc., No. 1:09-cr-10258	*
0678	United States v. Pharmacia & Upjohn Company, Inc., No. 1:09-cr-10258, Dkt. No. 2 (Plea agreement)	*
0679	Information document from United States v. Pharmacia & Upjohn Company, Inc., No. 1:09-cr-10258	*
0680	Attachment A to Dkt. No. 2 in Case No. 1:09-cr-10258-DPW	*
0681	Presentation re SAS 99 Brainstorming	*
0682	Transcript of Change of Plea	*
0683	Letter re Zyvox	*
0684	Letter from DOJ to the Honorable Douglas Woodlock re: United States v. Pharmacia & Upjohn Company, Inc., Criminal No. 09-10258-DPW	*
0685	Pfizer Form DEF 14A Proxy	*
0686	Study 1002 Reprint	*
0687	Pfizer Form DEF 14A Proxy	*
0688	Pfizer Form DEF 14A Proxy	*
0689	"Vast Mexico Bribery Case Hushed Up by Wal-Mart After Top-Level Struggle," by David Barstow, The New York Times, 22 April 2012	*
0690	Philips Purchase Confirmation	**
0691	Philips Purchase Confirmation	**
0692	Philips Purchase Confirmation	**
0693	Philips Purchase Confirmation	**
0694	Philips Purchase Confirmation	**

0695	Pfizer's Supplement and Verification to Pfizer's Supplement to Responses and Objections to Plaintiffs' First Set of Interrogatories in In re Pfizer Inc. Shareholder Derivative Litigation	**
------	--	----